Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients

Table 5

Clinical effects of the combination therapy with ETV plus BSF.

Group	Case	Sex (F/M)	Age (years)	Rates of virological response (%)	Rates of HBsAg decline ≥ 10% (%)
T1-Group	18	14/4	46.0 (36.5–49.5)	94.4	66.7
T2-Group	7	5/2	32.0 (29.0–36.0)	/	57.1
C1-Group	14	12/2	43.0 (37.5–49.5)	85.7	50.0
C2-Group	17	16/1	32.0 (27.0–42.0)	/	52.9